Clinical trials · Boston, MA
Kidney Transplant Recipients clinical trials in Boston
We’re tracking 14 recruiting kidney transplant recipients studies with a site in or near Boston — including Early Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06751992RecruitingPhase 4
Thinking and memory with extended-release tacrolimus in kidney transplant
This study tests if switching to an extended-release form of your anti-rejection medication (tacrolimus) helps protect memory and thinking skills. It is for older adults who have had a kidney transplant at least one year ago.
Boston, MassachusettsAges 65 years+ - NCT05900401RecruitingPhase 1/Phase 2
Immune tolerance study for kidney transplant recipients
This study tests whether giving a special mix of donor immune cells along with immune-suppressing medicines right after a kidney transplant can help the body accept the new kidney without long-term anti-rejection drugs. It aims to reduce the need for daily transplant medications.
Boston, MassachusettsAges 18–65 - NCT06126380Enrolling by invitationPhase 2
Long-term safety of tegoprubart in kidney transplant patients
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
Boston, MassachusettsAges 18–100 - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Boston, MassachusettsAges 18–70 - NCT04877288RecruitingPhase 3
Switch some teen kidney transplant patients to belatacept
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
Boston, MassachusettsAges 12–17 - NCT07434869Recruiting
Blood and image markers for ECP response in lung transplant CLAD
This study looks at whether blood tests and MRI scans can predict how well ECP (a blood-filtering treatment) works for people with CLAD after a lung transplant. If you’ve been prescribed ECP for CLAD and haven’t had it before, you may be able to help researchers find better ways to tailor treatment.
Boston, MassachusettsAges 7 years+ - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Boston, MassachusettsAges 13–20 - NCT04128189RecruitingPhase 3
Shingrix vaccine for people waiting for a kidney transplant
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
Boston, MassachusettsAges 18–70 - NCT07006831Recruiting
Blood study for kidney transplant patients
This study collects blood and leftover donor samples from kidney transplant recipients who need a biopsy. The goal is to improve monitoring after transplant.
Boston, MassachusettsAges 18 years+ - NCT05626530RecruitingPhase 4
Letermovir to prevent CMV after transplant illness
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
Boston, MassachusettsAges 18–75 - NCT07358195RecruitingEarly Phase 1
Combined stem cell and kidney transplant from a relative
This trial tests a combined transplant of blood-forming stem cells and a kidney from the same family member. It aims to help people with both advanced kidney failure and a blood cancer by potentially reducing the need for lifelong anti-rejection medicines.
Boston, MassachusettsAges 18–70 - NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Worcester, MassachusettsAges 18–70 - NCT05702398RecruitingEarly Phase 1
Vitamin A and niacinamide for high-risk skin cancer
This early trial tests whether adding vitamin A and niacinamide (a form of vitamin B3) can help people with a history of certain skin cancers reduce new disease. It is designed for adults with specific prior skin cancer or skin lesion treatment patterns.
Providence, Rhode IslandAges 18 years+
Hear when a new Kidney Transplant Recipients trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Where these studies are running near Boston
Institutions with a site for the recruiting kidney transplant recipients studies listed above.
- Massachusetts General Hospital · 5 studies
- Brigham and Women's Hospital · 3 studies
- Boston Children's Hospital (Site #: 71001)
- Local Institution - 0044
- Massachusetts General Hospital: Transplantation
- MGH Kidney Transplant Clinic
- Rhode Island Hospital
- Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases
What taking part in a kidney transplant recipients study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there kidney transplant recipients clinical trials near Boston?
- Yes. We're currently tracking 14 recruiting kidney transplant recipients studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a kidney transplant recipients study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a kidney transplant recipients trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New kidney transplant recipients studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.